• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Genocea Biosciences

edit

Genocea is developing a new class of human vaccines based on a revolutionary platform for the rapid discovery of antigens that induce T cell immunity. The platform, which dramatically reduces the time to discover vaccine candidates, uniquely employs a proprietary, high-throughput approach that mimics the natural immune response in the laboratory to comprehensively screen for antigens that are protective across diverse human populations. Genocea has demonstrated preclinical proof-of-concept with vaccines for herpes simplex virus type 2 (HSV-2), Streptococcus pneumoniae, and Chlamydia trachomatis, infections that affect hundreds of millions of people worldwide. The company expects to begin clinical trials for its lead program, a therapeutic vaccine for HSV-2, in early 2011.

Milestones

edit

• 
  Genocea Biosciences added Chip Clark as CEO.
  Posted 8/18/10 at 6:27pm
• 
  Genocea Biosciences received $35M in Series B funding. (1/3/11)
  Posted 1/3/11 at 6:08pm via finsmes.com
• 
  Genocea Biosciences — has promoted chief business officer Chip Clark to president and CEO (2/1/11)
  Posted 2/2/11 at 5:10am via masshightech.com
• 
  Genocea Biosciences — nine venture capitalists, including three new ones, invested $35 million in a Series B round (1/5/11)
  Posted 1/6/11 at 5:17am via masshightech.com

Videos

Screenshots

edit

Sources

1. Genocea Biosciences Closes $35M Series B Financing Round (finsmes.com) [edit]
Genocea's $35M VC round pushing herpes vaccine toward clinic (masshightech.com) [edit]
Clark named CEO at Genocea Biosciences (masshightech.com) [edit]